Archives of Gynecology and Obstetrics

, Volume 252, Issue 1, pp 49–53

Influence on erythropoietin levels of treatment with cisplatinum-endoxan

Authors

  • W. Lechner
    • Department of Obstetrics and GynecologyUniversity of Innsbruck
  • E. Artner-Dworzak
    • Institute of Medical ChemistryUniversity of Innsbruck
  • E. Sölder
    • Department of Obstetrics and GynecologyUniversity of Innsbruck
  • M. Sachsenmaier
    • Department of Obstetrics and GynecologyUniversity of Innsbruck
  • D. Kölle
    • Department of Obstetrics and GynecologyUniversity of Innsbruck
  • H. Moncayo
    • Department of Obstetrics and GynecologyUniversity of Innsbruck
  • R. Reitsamer
    • Department of Obstetrics and GynecologyUniversity of Innsbruck
Originals

DOI: 10.1007/BF02389607

Cite this article as:
Lechner, W., Artner-Dworzak, E., Sölder, E. et al. Arch Gynecol Obstet (1992) 252: 49. doi:10.1007/BF02389607

Summary

Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.

Key words

ErythropoietinCytostatic agentsCisplatinumEndoxan

Copyright information

© Springer-Verlag 1992